AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing
AstraZeneca posts strong Q3; RBC raises target, citing reduced AVANZAR uncertainty and promising pipeline catalysts.
Share
Why It Matters
AstraZeneca had a good quarter and an expert raised their price goal. This hints the company might be on a better track ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.